Literature DB >> 4040410

Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits.

G Agnelli, M R Buchanan, F Fernandez, J Van Ryn, J Hirsh.   

Abstract

Tissue type plasminogen activator (t-PA) is an effective thrombolytic agent in experimental animals. The duration of the thrombolytic effect of infused t-PA is unknown. We compared the duration of the thrombolytic effect of t-PA with streptokinase by measuring the lysis of 125I-fibrin-labeled thrombi in rabbit jugular veins at different times after a bolus injection of the fibrinolytic agents. The pharmacodynamics of both thrombolytic agents were determined in rabbits using a sensitive ex vivo fibrinolytic assay. Streptokinase and t-PA were given as a bolus dose of 15,000 U/kg. There was no detectable circulating fibrinolytic activity 30 minutes after the bolus dose of t-PA and 120 minutes after the bolus dose of streptokinase. The t-PA injection produced 34% thrombolysis at 30 minutes, 90% thrombolysis at 120 minutes, and 96% thrombolysis at 240 minutes. The streptokinase injection produced 17% thrombolysis at 30 minutes, 34% at 120 minutes, and 34% at 240 minutes. These observations indicate that the thrombolytic effect of t-PA is sustained beyond its time of clearance from the circulation whereas the thrombolytic effect of streptokinase closely parallels its activity in the circulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 3.  Case study and review: treatment of tricuspid prosthetic valve thrombosis.

Authors:  David Yi Zhang; Jay Lozier; Richard Chang; Vandana Sachdev; Marcus Y Chen; Jennifer L Audibert; Keith A Horvath; Douglas R Rosing
Journal:  Int J Cardiol       Date:  2011-10-14       Impact factor: 4.164

4.  Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis.

Authors:  Richard Chang; McDonald K Horne; Thomas H Shawker; Anthony W Kam; Enn Alexandria Chen; Galen O Joe; Willie L Ching; Edie Mao; David A Wyrick; Jay N Lozier
Journal:  J Vasc Interv Radiol       Date:  2011-06-12       Impact factor: 3.464

5.  Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation.

Authors:  Richard Chang; John A Butman; Russell R Lonser; Richard M Sherry; Prakash K Pandalai; McDonald K Horne; Jay N Lozier
Journal:  J Vasc Interv Radiol       Date:  2013-01       Impact factor: 3.464

6.  Biochemical dynamics relevant to the safety of low-dose, intraclot alteplase for deep vein thrombosis.

Authors:  Jay N Lozier; Ann M Cullinane; Khanh Nghiem; Richard Chang; McDonald K Horne
Journal:  Transl Res       Date:  2012-02-23       Impact factor: 7.012

Review 7.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 8.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

9.  The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation.

Authors:  S Akasaka; H Nishi; M Aoe; H Date; A Andou; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

10.  Pulsed-high intensity focused ultrasound enhanced tPA mediated thrombolysis in a novel in vivo clot model, a pilot study.

Authors:  Michael J Stone; Victor Frenkel; Sergio Dromi; Peter Thomas; Ryan P Lewis; King C P Li; McDonald Horne; Bradford J Wood
Journal:  Thromb Res       Date:  2007-05-04       Impact factor: 3.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.